Tampa, FL – June 28, 2023 – Verséa Health, Inc., a prominent provider of diagnostics and medical supplies for urgent care centers, and iRemedy Healthcare Companies, Inc. (“iRemedy”), a trailblazer in the medical supply e-commerce industry, are thrilled to announce their strategic joint venture. The collaboration aims to establish an integrated ecosystem of services tailored...
Tampa, FL. — Verséa Health, Inc. has partnered with Doc Johnson to launch a new Doc Johnson Wellness Center display available to retailers. This exclusive new partnership will provide Doc Johnson customers with access to cutting-edge diagnostics, treatments and preventive care services that are tailored to their individual needs. The Doc Johnson Wellness Center will include...
At this year’s NACS Show 2022 Verséa Holdings, Inc. is launching their new business division Verséa Health and their Product Line Portfolio Verséa Easy Lab™. James Olin, Chief Commercial Officer at Verséa, explains the reason behind the launch: “Verséa Health was created with a mission to give millions of Americans direct-access to the most essential...
Verséa Holdings, Inc. ( Verséa ) has donated thousands of rapid antigen COVID-19 test kits to the University of South Florida (USF) for use by students on all three campuses. This gift – valued at over $1.1 million – aligns with Verséa’s and USF’s shared commitment to supporting the development and health of the Tampa...
Two new strains of COVID that appear to be more transmissible than even “stealth Omicron,” and that have the ability to evade antibodies from vaccination and prior infection, have arrived in the U.S.—and they could mean a new wave is coming. The World Health Organization (WHO) announced that it is tracking two new subvariants of...
According to the latest WHO and CDC reports, the new Omicron subvariant known as BA.2 is now dominant worldwide, prompting surges in many countries in Europe and Asia. It is rapidly spreading in the United States and is more contagious than the original omicron and its variant BA.1, raising fears about another outbreak. The study...
According to recent reports, the new BA.2 COVID-19 variant (a subvariant of the omicron variant called BA.1.) spreads more easily than the original omicron. Early data suggest that BA.2 is about 30% more transmissible than the original variant. The new BA.2 variant can also manifest different symptoms than the original strains. New symptoms include: Dizziness Fatigue...
Yesterday the WHO’s Technical Advisory Group on SARS-Cov-2 Virus Evolution (ATG-VE) published a statement on new omicron variants that have been circulating globally, accounting for nearly all sequences reported to GISAID: “Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, the group reinforced that the BA.2 sublineage should continue to...
Researchers screen rapid-detection COVID-19 tests for sensitivity/specificity, limit of detection, and time to results ANN ARBOR, MI, and VANCOUVER, BC—February 10, 2021—After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified five direct (antigen/RNA) tests for detection of acute infection and six indirect (antibody) tests for...
Collaboratively administrate turnkey channels whereas virtual e-tailers. Objectively seize scalable metrics whereas proactive e-services. Dynamically procrastinate B2C users after installed base benefits. Dramatically visualize customer directed convergence without revolutionary ROI.
© 2022 Verséa Health, Inc. All rights reserved.